Developer docs
API playgroundTry for free, no card

Search company profiles

Brawn Biotech

Full company profile

uuid003hs6t

Namestring
Brawn Biotech
Legal namestring
Brawn Biotech Ltd.
Company typeenum
Public
Founded yearint
1986
Descriptiontext

Brawn Biotech Ltd. (formerly Brawn Pharmaceuticals Ltd.) is a publicly listed Indian pharmaceutical formulations distributor headquartered in New Delhi. Founded in 1986 and listed on the Bombay Stock Exchange (BSE Code: 530207) and Delhi Stock Exchange since 1995, the company distributes a broad portfolio of pharmaceutical formulations spanning twelve therapeutic segments: Antibacterials, Cardiovasculars, Antidiabetics, Analgesics, Gastrointestinals, Antifungals, Skin Care, Antipsychotics, Antiasthmatics, Antacids, Antimalarials, and Nutritionals. It also markets select branded specialty products such as LITHIN-S (Lecithin 525mg + Silymarin 150mg soft gel capsule for liver health).

The company operates a B2B enterprise field sales model, distributing products directly to government health institutions, hospitals, and pharmacies across India and international markets where it holds product registrations. Its go-to-market relies on institutional sales relationships built over 39 years of operation and regulatory registrations that create barriers to entry in government supply channels. The promoter and promoter group hold approximately 53.6-53.7% of shares, with the remainder distributed across approximately 3,966 public shareholders as of September 2025.

Brawn Biotech employs between 1,001 and 5,000 people and has total paid-up capital of 30,00,300 equity shares of Rs. 10 each. Its revenue model centers on one-time sales of pharmaceutical formulations across therapeutic categories, with pricing details not publicly disclosed. The company has no disclosed AI capabilities, no recent acquisitions or partnerships, and shows limited recent strategic activity beyond governance housekeeping (director regularization in 2024, SEBI compliance updates).

Short descriptiontext

Brawn Biotech Ltd. is a publicly listed Indian pharmaceutical formulations distributor, founded in 1986 and headquartered in New Delhi, serving government health institutions, hospitals, and pharmacies in India and international markets across twelve therapeutic segments.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew Delhi, India
HQ citystring
New Delhi
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmaceutical formulations, antidiabetic medications, antibacterial drugs, liver health supplements, cardiovascular medications
Industry3 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRADAGAD
Herbal & Botanical Supplements
SECONDARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Medicinal and Botanical Manufacturing325411
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
SIC code3 codes
  • Pharmaceutical Preparations2834
  • Medicinal Chemicals & Botanical Products2833
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Pharmaceutical Formulations
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Formulations Sales
TypeOne Time License
Description

Distribution of pharmaceutical formulations across multiple therapeutic segments including Antibacterials, Cardiovasculars, Antidiabetics, Analgesics, Gastrointestinals, Antifungals, Skin Care, Antipsychotics, Antiasthmatics, Antacids, Antimalarials, and Nutritionals in domestic and international markets.

brawnbiotech.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Brawn Biotech Ltd. manufactures and distributes pharmaceutical formulations across twelve therapeutic segments including Antibacterials, Cardiovasculars, Antidiabetics, Analgesics, Gastrointestinals, Antifungals, Skin Care, Antipsychotics, Antiasthmatics, Antacids, Antimalarials, and Nutritionals. The company also markets branded products such as LITHIN-S (Lecithin 525mg + Silymarin 150mg Soft Gel Capsule) for liver health, supplying health institutions, pharmacies, and government departments in India and international markets.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Brawn Biotech is a pharmaceutical distribution company that offers a broad portfolio of pharmaceutical formulations covering therapeutic segments including Antibacterials, Cardiovasculars, Antidiabetics, Analgesics, Gastrointestinals, Antifungals, Skin Care, Antipsychotics, Antiasthmatics, Antacids, Antimalarials, and Nutritionals. The company also markets specific branded products such as LITHIN-S (Lecithin + Silymarin soft gel capsule for liver health). The company operates in both domestic Indian markets and international markets.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Recent move8 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
1Sun Pharmaceutical Industries
TypeBroad incumbent
Description

Largest Indian generic pharmaceutical company with the broadest therapeutic portfolio in the country; the dominant incumbent against whom mid/small-cap players like Brawn Biotech compete in domestic and international tenders.

TypeDirect peer
Description

Mid-tier Indian generic pharmaceutical manufacturer with a similarly diversified portfolio spanning anti-infectives, cardiovascular, anti-diabetic, and pain management segments; comparable therapeutic breadth and institutional/government sales channels in domestic and emerging markets.

TypeBroad incumbent
Description

Major Indian generic pharma with cardiovascular, anti-diabetic, anti-infective, and respiratory focus — directly overlapping Brawn's therapeutic portfolio; incumbent reference point for institutional tender pricing.

TypeDirect peer
Description

Indian pharma company with comparable mix of domestic institutional sales and international exports, focused on generics and specialty pharma; similar mid-cap positioning and regulatory-registration-driven go-to-market.

TypeBroad incumbent
Description

Major Indian pharma incumbent with deep presence in respiratory, anti-infective, and cardiovascular generics — categories where Brawn also competes; serves as a benchmark for scale, regulatory capability, and export footprint.

TypeBroad incumbent
Description

Large Indian multinational generic and specialty pharma company with significant international product registrations; representative incumbent whose export playbook mirrors Brawn's stated strategy.

TypeEmerging player
Description

Smaller Indian pharma with presence in formulations and contract manufacturing; illustrates the small/mid-cap tier in which Brawn Biotech operates and the competitive dynamics of niche Indian formulators.

TypeDirect peer
Description

Indian generic pharma with overlapping therapeutic segments (anti-infectives, cardiology, anti-diabetic) and active institutional/government sales; similar size tier and business model as Brawn Biotech.

TypeDirect peer
Description

Mid-sized Indian specialty generic manufacturer with broad therapeutic coverage and strong presence in emerging-market institutional channels; closely comparable in scale, therapeutic breadth, and B2B distribution model.

TypeDirect peer
Description

Indian generic pharma company of similar scale with multi-therapeutic coverage including gastrointestinal, cardiovascular, and anti-infectives; competes directly for institutional tenders and distributor relationships in India.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Brawn Biotech

Pharmaceutical Formulationsbrawnbiotech.com

Brawn Biotech Ltd. is a publicly listed Indian pharmaceutical formulations distributor, founded in 1986 and headquartered in New Delhi, serving government health institutions, hospitals, and pharmacies in India and international markets across twelve therapeutic segments.

What Brawn Biotech does

Brawn Biotech Ltd. (formerly Brawn Pharmaceuticals Ltd.) is a publicly listed Indian pharmaceutical formulations distributor headquartered in New Delhi. Founded in 1986 and listed on the Bombay Stock Exchange (BSE Code: 530207) and Delhi Stock Exchange since 1995, the company distributes a broad portfolio of pharmaceutical formulations spanning twelve therapeutic segments: Antibacterials, Cardiovasculars, Antidiabetics, Analgesics, Gastrointestinals, Antifungals, Skin Care, Antipsychotics, Antiasthmatics, Antacids, Antimalarials, and Nutritionals. It also markets select branded specialty products such as LITHIN-S (Lecithin 525mg + Silymarin 150mg soft gel capsule for liver health).

The company operates a B2B enterprise field sales model, distributing products directly to government health institutions, hospitals, and pharmacies across India and international markets where it holds product registrations. Its go-to-market relies on institutional sales relationships built over 39 years of operation and regulatory registrations that create barriers to entry in government supply channels. The promoter and promoter group hold approximately 53.6-53.7% of shares, with the remainder distributed across approximately 3,966 public shareholders as of September 2025.

Brawn Biotech employs between 1,001 and 5,000 people and has total paid-up capital of 30,00,300 equity shares of Rs. 10 each. Its revenue model centers on one-time sales of pharmaceutical formulations across therapeutic categories, with pricing details not publicly disclosed. The company has no disclosed AI capabilities, no recent acquisitions or partnerships, and shows limited recent strategic activity beyond governance housekeeping (director regularization in 2024, SEBI compliance updates).

Brawn Biotech firmographics

Firmographics
Name
Brawn Biotech
Legal name
Brawn Biotech Ltd.
Website
https://brawnbiotech.com
Company type
Public
Founded year
1986
Operating status
Operating
Headcount range
11–50 employees
Short description
Brawn Biotech Ltd. is a publicly listed Indian pharmaceutical formulations distributor, founded in 1986 and headquartered in New Delhi, serving government health institutions, hospitals, and pharmacies in India and international markets across twelve therapeutic segments.
Ownership category
akta.pro rank

Brawn Biotech industry classification

Industry
Product category
Pharmaceutical Formulations
NAICS
Pharmaceutical Preparation Manufacturing (325412), Medicinal and Botanical Manufacturing (325411), Drugs and Druggists' Sundries Merchant Wholesalers (424210)
SIC
Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYCRADAGAD
Herbal & Botanical Supplements
SECONDARYEUAAAIAK
Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives
Energy, Utilities & Environment/Bioenergy, Natural Gas & Biomass/Biorefining & Bio-based Chemicals (Co-products, Bioproducts)

Keywords

  • Pharmaceutical formulations
  • Antidiabetic medications
  • Antibacterial drugs
  • Liver health supplements
  • Cardiovascular medications

Where Brawn Biotech is headquartered

Location

Headquarters

HQ city
New Delhi
HQ country
India
HQ region
Asia

Offices1 record

Markets served

Brawn Biotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D

Revenue model

  1. Pharmaceutical Formulations Sales: Distribution of pharmaceutical formulations across multiple therapeutic segments including Antibacterials, Cardiovasculars, Antidiabetics, Analgesics, Gastrointestinals, Antifungals, Skin Care, Antipsychotics, Antiasthmatics, Antacids, Antimalarials, and Nutritionals in domestic and international markets.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Brawn Biotech product offering

Product offering

Core offering

Brawn Biotech Ltd. manufactures and distributes pharmaceutical formulations across twelve therapeutic segments including Antibacterials, Cardiovasculars, Antidiabetics, Analgesics, Gastrointestinals, Antifungals, Skin Care, Antipsychotics, Antiasthmatics, Antacids, Antimalarials, and Nutritionals. The company also markets branded products such as LITHIN-S (Lecithin 525mg + Silymarin 150mg Soft Gel Capsule) for liver health, supplying health institutions, pharmacies, and government departments in India and international markets.

Product overview

Brawn Biotech is a pharmaceutical distribution company that offers a broad portfolio of pharmaceutical formulations covering therapeutic segments including Antibacterials, Cardiovasculars, Antidiabetics, Analgesics, Gastrointestinals, Antifungals, Skin Care, Antipsychotics, Antiasthmatics, Antacids, Antimalarials, and Nutritionals. The company also markets specific branded products such as LITHIN-S (Lecithin + Silymarin soft gel capsule for liver health). The company operates in both domestic Indian markets and international markets.

Differentiator

Problem solved

Functional benefit

Companies that use Brawn Biotech

Customer profile

Segments1 record

Ideal customer profiles1 record

Brawn Biotech technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Brawn Biotech partnerships and signals

Strategic signal

Scale indicators4 records

Recent moves8 records

Expansion highlights3 records

Brawn Biotech competitors and assessment

Company assessment

Broad incumbents

  • Sun Pharmaceutical Industries: Largest Indian generic pharmaceutical company with the broadest therapeutic portfolio in the country; the dominant incumbent against whom mid/small-cap players like Brawn Biotech compete in domestic and international tenders.
  • Lupin: Major Indian generic pharma with cardiovascular, anti-diabetic, anti-infective, and respiratory focus — directly overlapping Brawn's therapeutic portfolio; incumbent reference point for institutional tender pricing.
  • Cipla: Major Indian pharma incumbent with deep presence in respiratory, anti-infective, and cardiovascular generics — categories where Brawn also competes; serves as a benchmark for scale, regulatory capability, and export footprint.
  • Dr. Reddy's Laboratories: Large Indian multinational generic and specialty pharma company with significant international product registrations; representative incumbent whose export playbook mirrors Brawn's stated strategy.

Direct peers

  • Ipca Laboratories: Mid-tier Indian generic pharmaceutical manufacturer with a similarly diversified portfolio spanning anti-infectives, cardiovascular, anti-diabetic, and pain management segments; comparable therapeutic breadth and institutional/government sales channels in domestic and emerging markets.
  • Natco Pharma: Indian pharma company with comparable mix of domestic institutional sales and international exports, focused on generics and specialty pharma; similar mid-cap positioning and regulatory-registration-driven go-to-market.
  • Alembic Pharmaceuticals: Indian generic pharma with overlapping therapeutic segments (anti-infectives, cardiology, anti-diabetic) and active institutional/government sales; similar size tier and business model as Brawn Biotech.
  • Ajanta Pharma: Mid-sized Indian specialty generic manufacturer with broad therapeutic coverage and strong presence in emerging-market institutional channels; closely comparable in scale, therapeutic breadth, and B2B distribution model.
  • Unichem Laboratories: Indian generic pharma company of similar scale with multi-therapeutic coverage including gastrointestinal, cardiovascular, and anti-infectives; competes directly for institutional tenders and distributor relationships in India.

Emerging players

  • Windlas Biotech: Smaller Indian pharma with presence in formulations and contract manufacturing; illustrates the small/mid-cap tier in which Brawn Biotech operates and the competitive dynamics of niche Indian formulators.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Brawn Biotech social profiles

Digital presence

Brawn Biotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Brawn Biotech leadership team

Management profile

Number of profiles

Profiles8 records

Brawn Biotech funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Brawn Biotech M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Brawn Biotech

What does Brawn Biotech do?

Brawn Biotech Ltd. manufactures and distributes pharmaceutical formulations across twelve therapeutic segments including Antibacterials, Cardiovasculars, Antidiabetics, Analgesics, Gastrointestinals, Antifungals, Skin Care, Antipsychotics, Antiasthmatics, Antacids, Antimalarials, and Nutritionals. The company also markets branded products such as LITHIN-S (Lecithin 525mg + Silymarin 150mg Soft Gel Capsule) for liver health, supplying health institutions, pharmacies, and government departments in India and international markets.

Is Brawn Biotech a public or private company?

Brawn Biotech is a public company. It is classified as public and is currently operating.

When was Brawn Biotech founded?

Brawn Biotech was founded in 1986. It employs 11 to 50 people.

Where is Brawn Biotech based?

Brawn Biotech is headquartered in New Delhi, India, in the Asia region.

How does Brawn Biotech make money?

One revenue line is on record: pharmaceutical Formulations Sales.

Who are Brawn Biotech's main competitors?

Broad incumbents on record are Sun Pharmaceutical Industries, Lupin, Cipla and Dr. Reddy's Laboratories. Direct peers are Ipca Laboratories, Natco Pharma, Alembic Pharmaceuticals, Ajanta Pharma and Unichem Laboratories. Windlas Biotech is listed as an emerging player.

Does Brawn Biotech have an API?

No public API is recorded for Brawn Biotech.

What industry is Brawn Biotech in?

Brawn Biotech's product category is Pharmaceutical Formulations. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of CRADAGAD, Herbal & Botanical Supplements. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals